Concert Pharmaceuticals
Dr. Christopher L. Brummel joined Concert in March 2015 and currently serves as Vice President, Drug Metabolism and Pharmacokinetics (DMPK) and Bioanalysis (BA). He has more than 24 years of experience in the pharmaceutical and biotechnology industry in the fields of DMPK, BA and Analytical Chemistry. Prior to joining Concert, Dr. Brummel worked at Vertex Pharmaceuticals and Celgene in DMPK and BA and Analytical Chemistry. He earned his Baccalaureate in Chemistry with Honors as a Carleton B Edwards scholar from Earlham College, a Ph.D. in Physical Chemistry and Biophysical Chemistry from Cornell University as an NIH predoctoral fellow, and was a postdoctoral fellow at The Pennsylvania State University.
This person is not in any offices
Concert Pharmaceuticals
Concert Pharmaceuticals is a clinical-stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to address unmet patient needs.